Also Read | Field report: A groundswell of anti-incumbency in Mamata’s BengalCadila Healthcare did not provide further details on the settlement, and emailed queries sent to the company spokesperson await a reply.Patent for Revlimid, which is used to treat multiple myeloma and myelodysplastic syndromes, expires in March next year.
Bristol Myers Squibb (BMS), the parent of Celgene, had in 2020 garnered over $12 billion in sales from the drug, making it the largest drug in terms of sales for the parent, according to BMS’ financial statements for the year.Cadila Healthcare is the fifth company to settle litigation with Celgene over the patent after Cipla, Natco Pharma and Dr Reddy’s Laboratories.